MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Bristol Myers Squibb

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
News headline image
Bristol Myers Squibb Enters Into $5 Billion Aggregate Accelerated Share Repurchase Agreements
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Awards Nearly $8 Million in New Health Equity Grants to Improve Access to Care for Medically Underserved Patients in U.S.
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Century Therapeutics and Bristol Myers Squibb Enter into a Strategic Collaboration to Develop iPSC-derived Allogeneic Cell Therapies
From Bristol Myers Squibb
Via Business Wire
Tickers BMY IPSC
News headline image
Bristol Myers Squibb to Highlight Long-Term Growth Strategy at J.P. Morgan’s 40th Annual Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb to Present at J.P. Morgan’s 40th Annual Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb to Report Results for Fourth Quarter 2021 on February 4, 2022
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
U.S. Food and Drug Administration Approves Orencia® (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD)...
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401
From Bristol Myers Squibb
Via Business Wire
Tickers BMY IMTX
News headline image
Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM Study Results
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
U.S. Food and Drug Administration Accepts for Priority Review supplemental Biologics License Application for Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Announces New PDUFA Date for Mavacamten
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Awards “Golden Tickets” to Promising Biotechs for Residencies at LabCentral, Biolabs@NYULangone and MBC BioLabs
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Late-Breaking Phase 2 Data for Investigational Oral Factor XIa Inhibitor Milvexian Suggest Favorable Antithrombotic Profile Across a Wide Range of Doses
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Launches Could It Be HCM? Campaign to Increase Awareness of Hypertrophic Cardiomyopathy (HCM), the Most Common Inherited Heart Disease
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb to Take Part in Wolfe Research Virtual Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb to Present Data Across Robust Cardiovascular Portfolio at American Heart Association Scientific Sessions 2021
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb to Highlight More than 80 Abstracts at ASH 2021 Demonstrating Strength of Innovative Therapeutic Platforms Improving Outcomes for a Broad Range of Hematologic Diseases
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Data at ACR Convergence 2021 Illustrate Scientific Advances for Immune-Mediated Rheumatic Diseases
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Announces Earnings Call Time Change; Third Quarter 2021 Earnings Call to Occur on October 27, 2021 at 10 a.m. (Eastern Time)
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) + Chemotherapy for Patients with HER2 Negative, Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma …
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
The Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program Announces First Group of Physicians to be Trained
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
News headline image
Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis
From Bristol Myers Squibb
Via Business Wire
Tickers BMY
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story